Nanomedicine in Cancer Immunotherapy
- 1st Edition - January 11, 2024
- Imprint: Academic Press
- Editor: Prashant Kesharwani
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 1 8 7 7 0 - 4
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 8 7 7 1 - 1
Nanomedicine in Cancer Immunotherapy bridges the two disciplines of nanotechnology and immunology, summarizing the latest research into novel cancer treatments, often person… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteNanomedicine in Cancer Immunotherapy bridges the two disciplines of nanotechnology and immunology, summarizing the latest research into novel cancer treatments, often personalized to the patient. The book covers a wide range of nanomaterial types for use in cancer immunotherapy, including hydrogel, lipid, exosome, gold and peptide nanoparticles. The preparation, application, pros and cons of each nanomaterial class is reviewed, helping the reader understand the potential for each to tailor their own selections. Nanovaccines are also covered, along with a clinical evaluation and market analysis of nanomedicines for immunotherapy, offering an important clinical and commercial overview of this rapidly developing field.
This book is an interesting reference for those working in the fields of nanotechnology, immunology, and cancer therapeutics, as well as clinicians with an interest in novel nano-based cancer treatments.
This book is an interesting reference for those working in the fields of nanotechnology, immunology, and cancer therapeutics, as well as clinicians with an interest in novel nano-based cancer treatments.
- Provides a single source for a review of the latest research in the development of nanomaterials for cancer immunotherapy
- Introduces the reader to basic principles of immunology and immunotherapy to aid our understanding
- Details a wide range of nanomaterial classes for cancer immunotherapy, with advantages and disadvantages thoroughly analyzed
Researchers and postgraduate students in the fields of materials science, biomedical engineering, pharmaceutical science and nanotechnology, Clinical scientists and R&D groups developing novel materials for biomedical applications
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- List of contributors
- About the editor
- Preface
- Acknowledgments
- Chapter 1. Immunoadjuvants for cancer immunotherapy
- Abstract
- 1.1 Why adjuvants for cancer immunotherapy?
- 1.2 Nanostructures for cancer immunotherapy
- 1.3 Viruses against cancer
- 1.4 Combined approaches for immunotherapy against cancer
- 1.5 Emerging cationic nanoadjuvants for cancer immunotherapy
- Acknowledgments
- References
- Chapter 2. Nanotechnology as an emerging option in cancer immunotherapy
- Abstract
- 2.1 Introduction
- 2.2 Traditional methods used in cancer treatment
- 2.3 Cancer immunotherapy
- 2.4 Different adoptive cellular transfer immunotherapies strategies for cancer
- 2.5 Nanotechnology-associated cancer immunotherapy strategies
- 2.6 Types of nanoparticles used in cancer immunotherapy
- 2.7 The targeted delivery of nanoparticles with cancer immunotherapy
- 2.8 Direct immune checkpoint inhibition with nanoparticles
- 2.9 Conclusion
- References
- Further reading
- Chapter 3. Different administration routes for nanovectors in cancer immunotherapy
- Abstract
- 3.1 Introduction
- 3.2 Types of nanovectors used in cancer immunotherapy
- 3.3 Deficiencies in delivery and efficacy of nanovectors
- 3.4 Nanovectors targeting mechanisms
- 3.5 Nanovectors’ administration routes
- 3.6 Transdermal delivery
- 3.7 Subcutaneous delivery
- 3.8 IV delivery
- 3.9 Oral delivery
- 3.10 Inhalation (pulmonary) delivery
- 3.11 Intramuscular delivery
- 3.12 Intraperitoneal delivery
- 3.13 Intranasal delivery
- 3.14 Rectal delivery
- 3.15 Vaginal delivery
- 3.16 IT delivery
- 3.17 Conclusion and future prospects
- References
- Chapter 4. Two-dimensional material–based nanomedicines for cancer immunotherapy
- Abstract
- 4.1 Introduction
- 4.2 Main 2D materials and their applications in cancer immunotherapy
- 4.3 Summary and perspectives
- Acknowledgments
- Conflicts of interest
- References
- Chapter 5. Hydrogel-based nanomedicines for cancer immunotherapy
- Abstract
- 5.1 Introduction
- 5.2 Nanotechnology and nanomedicine
- 5.3 Role of nanotechnology in cancer immunotherapy
- 5.4 Nanomaterials
- 5.5 Hydrogels
- 5.6 Hydrogel-based approaches in cancer immunotherapy
- 5.7 Conclusion and future perspective
- References
- Chapter 6. Exosomes-based nanomedicines for cancer immunotherapy
- Abstract
- 6.1 Introduction
- 6.2 Exosomes for cancer immunotherapy
- 6.3 Summary
- Acknowledgment
- Conflict of interest
- References
- Chapter 7. Lipid-based nanomedicines for cancer immunotherapy
- Abstract
- 7.1 Introduction
- 7.2 Cancer immunotherapy
- 7.3 Immunotherapeutic delivery systems
- 7.4 Different kinds of nanocarriers that are based on lipids
- 7.5 Oral lipid nanomedicines
- 7.6 Conclusions
- References
- Chapter 8. Inorganic nanoparticle-based nanomedicines for cancer immunotherapy
- Abstract
- 8.1 Introduction of cancer immunotherapy
- 8.2 Advantages of inorganic nanomaterials
- 8.3 Silica nanomaterials for immunotherapy
- 8.4 Gold-nanomaterials for immunotherapy
- 8.5 Copper-nanomaterials for immunotherapy
- 8.6 Magnetic nanomaterials for immunotherapy
- 8.7 Carbon-nanomaterials for immunotherapy
- 8.8 Quantum dots for immunotherapy
- 8.9 Conclusion and perspective
- Acknowledgments
- Conflict of interests
- References
- Further reading
- Chapter 9. Liposome-based nanomedicines for cancer immunotherapy
- Abstract
- 9.1 Introduction
- 9.2 Cancer immunotherapy
- 9.3 Nanomedicine in cancer immunotherapy
- 9.4 Liposomes: an overview
- 9.5 Liposomes in cancer immunotherapy
- 9.6 Challenges and future prospects
- 9.7 Conclusion
- Acknowledgement
- Conflict of interest
- References
- Chapter 10. Biomembrane-based nanoparticles for cancer immunotherapy
- Abstract
- 10.1 Red blood cell membrane-based nanoparticles
- 10.2 White blood cell membrane-based nanoparticles
- 10.3 Platelet membrane-based nanoparticles
- 10.4 Mesenchymal stem cell membrane-based nanoparticles
- 10.5 Cancer cell membrane-based nanoparticles
- 10.6 Bacterial membrane-based nanoparticles
- 10.7 Hybrid biomembrane-based nanoparticles
- 10.8 Conclusion and outlook
- References
- Chapter 11. Dendrimer-based nanomedicines for cancer immunotherapy
- Abstract
- 11.1 Introduction
- 11.2 Synthesis and characterization of dendrimer nanoparticles
- 11.3 Dendrimers as general carriers for drug delivery
- 11.4 Dendrimer and enhancement of cancer immune responses
- 11.5 Dendrimers as vehicles for cancer immunotherapy
- 11.6 Dendrimer-based drug carriers in different cancers
- 11.7 Conclusions and future perspectives
- References
- Chapter 12. Magnetic nanocarriers for cancer immunotherapy
- Abstract
- 12.1 Cancer immunotherapy
- 12.2 Magnetic nanocarriers
- 12.3 Magnetic nanocarrier for cancer immunotherapy
- 12.4 Definition of hyperthermia
- 12.5 Magnetic vaccination
- 12.6 Magnetic nanoparticle nanotheranostics
- 12.7 Conclusion
- References
- Chapter 13. Inhaled delivery of immunotherapy for treatment of lung cancer
- Abstract
- 13.1 Types of lung tumors
- 13.2 Involvement of the immune system in the development of lung tumors
- 13.3 Potential immunotherapies for treatment of lung cancer
- 13.4 Limitations related to systemic immunotherapy
- 13.5 Advantages of pulmonary delivery of immunotherapy
- 13.6 Barriers facing pulmonary drug delivery
- 13.7 Efficient pulmonary drug delivery
- 13.8 Particulate systems criteria for efficient pulmonary drug delivery
- 13.9 Pulmonary drug delivery platforms
- 13.10 Examples of inhaled immunotherapy
- References
- Chapter 14. Nano-based vaccination and their administration routes in cancer immunotherapy
- Abstract
- 14.1 Introduction
- 14.2 Antigens and vaccinations widely used in cancer treatment
- 14.3 Immunotherapy and cancer immunomodulation target cells
- 14.4 Potential of nanoparticle for cancer vaccination
- 14.5 Nanocarrier design and immunological response: the role of physicochemical properties
- 14.6 Systems for the delivery of cancer vaccines via nanoparticles
- 14.7 Clinical translation of cancer vaccines
- 14.8 Discussion
- 14.9 Conclusion
- Data availability statement
- Ethics statement
- Acknowledgment
- Funding
- Conflict of interest
- Author contributions
- References
- Chapter 15. Current status, challenges, and future perspective of nanomedicine-based cancer immunotherapy
- Abstract
- 15.1 Introduction
- 15.2 Cancer immunotherapy
- 15.3 Types and features of nanoparticles used in cancer immunotherapy
- 15.4 Nanomedicines in cancer immunotherapy
- 15.5 The use of nanoparticles in cancer vaccines
- 15.6 Nanoparticles as immunotherapeutic agent carriers
- 15.7 The use of nanoparticles in monoclonal antibody therapy
- 15.8 Adoptive T-cell therapy using nanoparticles
- 15.9 Challenges of nanomedicine-based cancer immunotherapy
- 15.10 Future prospects
- 15.11 Conclusion
- Acknowledgement
- Conflict of interest
- References
- Index
- Edition: 1
- Published: January 11, 2024
- No. of pages (Paperback): 500
- No. of pages (eBook): 500
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780443187704
- eBook ISBN: 9780443187711
PK
Prashant Kesharwani
Dr. Prashant Kesharwani is assistant professor of Pharmaceutics at Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, Madhya Pradesh, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 350 international publications in well-reputed journals and more than 25 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as “USERN Laureate award”, most prestigious “SERB-Ramanujan Fellowship Award”. He actively participates in outreach and scientific dissemination for the service of the wider community. His Number of citations is = 26779; h-index = 85; i-10 index = 370 (According to google scholar on March 2025). He has more than 30 international publications published in very high impact factor journals (Progress in Polymer Sciences IF 32.063, Molecular Sciences IF 41.444, Progress in Material Sciences IF 48.580, Advanced Materials IF 29.4, Drug Resistance Update IF 22.841 and Material Todays IF 32.072). He has presented many invited talks and oral presentations at prestigious scientific peer-conferences, received international acclaims and awards for research contribution, supervised students/junior researchers and actively participated in outreach and scientific dissemination for the service of the wider community.
Affiliations and expertise
Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, Madhya Pradesh, 470003, IndiaRead Nanomedicine in Cancer Immunotherapy on ScienceDirect